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Abstract—A set of bivalent mannose 6-phosphonate “molecular rulers” has been synthesized to examine ligand binding to the
M6P/IGF2R. The set is estimated to span a P-P distance range of 16-26 Å (MMFF energy minimization on the hydrated phosphonates).
Key synthetic transformations include sugar triflate displacement for phosphonate installation and Grubbs I cross-metathesis to achieve
bivalency. Relative binding affinities were tested by radioligand displacement assays versus PMP-BSA (pentamannose phosphate-bovine
serum albumin). These compounds exhibit slightly higher binding affinities for the receptor (IC50’s = 3.7-5 μM) than the parent,
monomeric mannose 6-phosphonate ligand and M6P itself (IC50 = 11.5 ± 2.5 μM). These results suggest that the use of an -configured
anomeric alkane tether is acceptable, as no significant thermodynamic penalty is apparently paid with this design. On the other hand, the
modest gains in binding affinity observed suggest that this ligand set has not yet found true bivalent interaction with the M6P/IGF2R (i.e.
binding to two distinct M6P-binding pockets).
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The mannose 6-phosphate/insulin-like growth factor II
receptor (M6P/IGF2R) is a type I transmembrane
glycoprotein that cycles through the Golgi, endosomes,
and the plasma membrane to carry out its role in the
transport of lysosomal enzymes to their cellular
destination.1 The receptor also functions in the binding,
uptake, and degradation of the mitogen, insulin-like
growth factor II (IGF-II) and facilitates activation of the
growth inhibitor, transforming growth factor-. The
ability of the M6P/IGF2R to inhibit cell proliferation, or
stimulate apoptosis, by these mechanisms has
implicated the receptor as a tumor suppressor. The
IGF-II binding activity of the M6P/IGF2R is mainly
responsible for its growth suppressor function. Many
cancers become growth factor-independent by highlevel expression of IGF-II, which not only binds to the
M6P/IGF2R, but also to the IGF1R. The high affinity
interaction of IGF-II with the IGF1R leads to activation
of IGF1R signaling pathways that promote cell division
and survival.2

Figure 1. M6P ligand binding to the M6P/IGF2R: The alternative “hook
and ladder” models: A. One monomeric unit of the M6P/IGF2R
consisting of the 15 extracellular repeating domains, transmembrane
domain, and a short cytoplasmic tail. The M6P/IGF2R is depicted as
forming a hook-like structure when a ligand bearing two M6P groups
binds to domains 3 and 9 (lighter shaded ovals). B. Two monomeric
units of the M6P/IGF2R are connected through binding by ligands that
interact with either domain 3 or 9 of two individual monomeric units to
form a dimeric ladder-like structure.
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Multivalent interactions between receptors and their
ligands,6 which are common in biology, involve a multistep mechanism in which most of the entropic cost is
paid by the initial binding event and subsequent
contacts contribute a favorable enthalpy without further
sacrifice of rotational and translational entropy.7 The
resultant high binding affinity in these interactions is
due to a reduced rate of ligand-receptor dissociation.
This type of interaction occurs in carbohydrate binding
to lectins and is particularly important in the binding of
M6P-bearing oligosaccharides by P-type lectins such as
the M6P/IGF2R.

Tong et al. demonstrated that there are two M6P
binding sites per monomeric unit of the M6P/IGF2R.8
Some native glycoprotein ligands and model
compounds (e.g. PMP-BSA) display up to 100- to 1000fold lower dissociation constants, i.e., higher affinities,
than ligands bearing a single phosphorylated
mannoside. Given that two M6P-binding pockets are
available per receptor in the monomeric binding model
and four per receptor in the dimeric model, bi- or
multivalency may account for this effect. This could
result from simultaneous contact with two M6P groups
on two distinct oligosaccharides. Alternatively, the
pioneering work of Varki and Kornfeld suggested that
such high affinity bivalent binding might also be
achieved with a single N-linked oligosaccharide
phosphorylated on the two ultimate mannose residues,
at the first and third antennae (Figure 2).9 This high
affinity could arise either from intramolecular contact
between a single receptor molecule and the two
phosphate groups on the ligand or by intermolecular
cooperation between two subunits within a dimeric
receptor structure, as depicted in Figure 1.
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The extracellular portion of the M6P/IGF2R contains 15
homologous repeat domains of ~147 amino acid
residues each. There are two M6P binding sites located
in domains 3 and 9, and there is one IGF-II binding site
in domain 11.3 Binding of high-affinity, M6P-based
ligands and rapid internalization of extracellular ligands,
such as IGF-II, are aided by the M6P/IGF2R’s ability to
dimerize.4,5
York et al. demonstrated that glucuronidase (hGUS), a homotetrameric lysosomal
enzyme bearing multiple M6P moieties, stabilized the
receptor’s dimeric structure by cross-bridging the M6P
binding sites on two adjacent subunits.5 These data
support a dimeric model for binding of bivalent M6Pbased ligands by the M6P/IGF2R (Figure 1).
Importantly, they also observed that hGUS binding
increased the rate of internalization of the receptor and
consequently stimulated the degradation of any
passenger ligands, including IGF-II, by 3- to 4-fold.
The long-term goal of the present work is to exploit this
unique property of bivalent M6P ligands as a potential
strategy for therapeutic intervention in IGF-IIdependent cancer.

Figure 2. Hindsgaul’s model biantennary ligands

Figure 3. Bock’s tripeptide bis-M6P-bearing ligands

Later work by the Hindsgaul group demonstrated that
the linkage between the ultimate Man and penultimate
Man on the phosphorylated branch is important, as an 1,2-glycosidic linkage results in a higher binding
affinity to the receptor than an -1,3-linkage (Figure
2).10 A series of synthetic multivalent ligands for the
M6P/IGF2R was prepared by Bock and coworkers,
using a glycopeptide design.11 The best of these
compounds bore two mannose disaccharides capped
with phosphate connected by a core peptide of 3 to 5
amino acids. A tripeptide version of this compound
bound the M6P/IGF2R with high affinity, which led to
the hypothesis of a bivalent M6P-based mechanism.5, 11
However, upon closer inspection, it appears that the
exceptional binding affinity of this compound was
attributable to an anthranoyl group present on the lysine
-amino group within the core peptide (Figure 3). This
modification increased the affinity by ~200-fold relative
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resistance to hydrolysis with the potential for improved
pharmacokinetics and efficacy in vivo. In light of the
aforementioned studies, we sought to improve affinity
by building bivalency into such ligands.
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We have recently demonstrated proof of principle for a
Ru-mediated cross-metathesis (CM) route to joining
two M6P surrogates, of both the malonate and
phosphonate varieties with a hydrocarbon tether.12
Herein, we describe the exploitation of this
methodology to synthesize a series of bis-M6Pphosphonates, with incrementally increasing tether
lengths as a sort of “molecular ruler” set to probe for
such a bivalent interaction with the receptor. To
systematically increase tether length in two carbon
increments, the initial mannosidation reaction was
performed with a series of terminally unsaturated
alcohols bearing 4-7 carbons [from 3-buten-1-ol
through 6-hepten-1-ol (Scheme 1).
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to the same compound with an unmodified peptide,11
presumably through interaction with a hydrophobic
patch on the receptor proximal to the M6P binding site.
Considering that the high affinity of this compound did
not arise from a bivalent M6P-based binding
mechanism, it is not surprising that York et al. found
that the compound failed to stabilize the receptor’s
dimeric structure or to stimulate its rapid
internalization.5 In summary, there is currently no
evidence in the literature of a small synthetic compound
capable of bivalent binding to the M6P/IGF2R by a
M6P-based mechanism.
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Initial studies pointed to the need for a modified
glycosylation protocol. The previous work employed
HCl gas-mediated glycosylation for allyl alcohol itself,
but this approach gave low yields, in the present work,
when applied to longer chain alcohols. Instead, it was
found that TMSOTf-mediated, Vorbrüggen-type
glycosylation, using an -mannosyl acetate glycosyl
donor was quite an efficient reaction. Alkene cross
metathesis14 and triflate displacement15 then followed as
the key steps, as before, in constructing these
compounds.
Following
a
final
alkene
hydrogenation/global debenzylation step, the free
tethered sugar phosphonates were obtained. Pleasingly,
even with the longest hydrocarbon tether lengths studied
here, no solubility issues were encountered in preparing
stock solutions up to 200 mM in a HEPES-saline buffer,
pH 7.4.
Table 1. Relative M6P/IGF2R binding affinities
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Scheme 1. Reagents and conditions: (a) NaH, BnBr, DMF, 0 °C to rt
(90%); (b) AcOH, Ac2 O, H 2SO 4, 0 °C (82%); (c) 2 TMSOTf, 3-buten-1ol, rt (86%); 3 TMSOTf, 4-penten-1-ol, rt (70%); 4 TMSOTf, 5-hexen-1ol, rt (63%); 5 TMSOTf, 6-hepten-1-ol, rt (62%); (d) Grubbs I catalyst,
DCM, 40 °C: 6 (81%); 7 (78%); 8 (69%); 9 (70%); (e) Sodium
methoxide, methanol, rt (quantitative); (f) 2,6-di-tert-butyl-4methylpyridine, Tf2O, DCM, -40 °C; (g) n-BuLi, dibenzyl methylphosphonate, THF, -78 °C (two step yields): 14 (67%); 15 (59%); 16
(33%); 17 (18%); (h) H2 (balloon pressure), Pd/C, rt; (i) NH4HCO3 (50
mM) aqueous solution, rt (two step yields): 18 (66%); 19 (71%); 20
(68%); 21 (62%).

Thus, the goal of this work is to develop high affinity
bivalent M6P-based ligands that accelerate disposal of
IGF-II as a passenger ligand directly in tumors, by
cross-bridging the M6P/IGF2R thereby enhancing its
ability to internalize IGF-II. In our previous work, we
discovered that the phosphonate is an excellent
surrogate for phosphate to promote equivalent
interaction with the M6P binding domains of the
M6P/IGF2R12,13 The phosphonate has the advantage of

a

Ligand

IC50(n) Ma

RBAb

Mr

Lgthc

M6P
G6P
18 (6C)

11.5 ± 2.51 (4)
>10 (4)
4.76 ± 2.50 (4)

1.0
NA
2.63 ± 0.74

340
282
666

19 (8C)

5.03 ± 1.34 (4)

2.39 ± 0.83

694

20 (10C)

4.44 ± 1.40 (4)

2.65 ± 0.52

722

21 (12C)

3.70 ± 0.56 (4)

3.02 ± 0.41

750

NA
NA
16.219.5 Å
19.220.9 Å
19.622.7 Å
24.626.0 Å

IC50 ’s for competitive displacement of radiolabeled PMP-BSA from the
receptor (n = no. of trials, see SI for details); G6P = glucose 6-phosphate
b
RBA = relative binding affinity, normalized to free M6P; c Length = P-P
distance, as estimated by molecular mechanics minimization (MMFF).
For each compound, minimizations were run from five different, chainextended starting conformers. The P-P distances given represent the
ranges seen for the set of low energy, chain-extended conformers found.
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Figure 4. One of several low energy chain-extended conformers found
by an MMFF molecular mechanics minimization on the hydrated 12carbon-spaced ligand. See Table 1 for the P,P-distance range found for
the set of such conformers.

In conclusion, this study introduces the design and
successful synthesis of the first array of bis-M6phosphonate-presenting “molecular rulers” to measure
distances between M6P-binding pockets at MPR’s, and
to
distinguish
between
intramolecular
and
intermolecular modes of bivalent binding. Although the
highest M6P/IGF2R binding affinity seen in the ligand
set is in the micromolar range [IC50 ~ 4 μM], no
solubility problems or tether penalty issues were
encountered. Moreover, the replacement of the M6P
ester with a hydrolytically stable phosphonate surrogate
persists as an effective design, across the entire set, and
reinforces the notion that phosphatase resistance can be
incorporated into such small molecule probes.
Completion of these studies will require that we find a
high-affinity ligand that stabilizes the dimeric structure
of the receptor and thereby promotes rapid
internalization of IGF-II in a cellular model.
Ultimately, a new compound that exhibits all these
properties would potentially be testable in an animal
model for inhibition for IGF-II-driven tumor growth.
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Dahms and coworkers performed very preliminary
modeling studies of the whole receptor, based on the
crystal structure of domains 1-3 using topographical
information based on the amino acid sequence of each
domain.16 Using this approach, they estimated the
intramolecular distance of closest approach between the
domain 3 and domain 9 M6P binding sites to be ~45 Å.
In contrast, they estimated the interphosphate distance
between the M6P caps of a bis-phosphorylated
oligosaccharide to be ~30 Å. For comparison, we
conducted modeling studies of our bis-phosphonate
ligands to determine if they could span these distances.
Using Spartan 04, we built the model structures of the
four compounds and added a cluster of six waters
around each phosphonate. In clustering these waters,
water-proton/phosphonate oxygen distances were set at
2.5 Å (hydrogen bonding distance). From energy
minimization by molecular mechanics methods (Spartan
04) using the Merck Molecular Force Field (MMFF),17
one obtains an estimate of the distance between the two
phosphorus atoms in each synthetic bis-phosphonate
(Table 1). The longest ligand could have a maximum
span of ~26 Å (Figure 4). Based on these estimates, our
compounds may still be too short to bind in a bivalent
manner, regardless of which receptor binding model is
correct.

hybridized alkane tether. Thus, each peptide bond
really represents a degree of pseudo-unsaturation
(planarity) with an expected bias toward a transoid
amide geometry.
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Relative binding affinities to M6P/IGF2R were
determined by displacement assay using radiolabeled
PMP-BSA as the tracer in the presence of increasing
concentrations of each of the synthetic ligands (Table
1). All the compounds in this new series showed IC50
values in the micromolar range with ~2-fold increase in
RBA compared to M6P alone. This small increase in
RBA likely results from the availability of 2 moles of
M6P per mole of ligand providing a 2-fold increase in
the effective competitor concentration, as opposed to
any effect of tether length. Thus, we conclude that
these synthetic compounds are binding the M6P/IGF2R
in a monovalent manner. Moreover, these results imply
that the two M6-phosphonate moieties are binding
essentially independently, and with no apparent
thermodynamic or conformational penalty paid for the
linker (possible issues include: position of attachment,
hydrophobicity, trajectory, etc.)
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In addition to the importance of tether length, the
structure of the tether is critical to development of a
high-affinity bivalent ligand. The adventitious binding
properties of the Bock compound suggest that additional
binding energy may be achieved by adjusting
hydrophobicity, charge and/or -surface of the tether.11
Moreover, the success enjoyed by the groups of Bock
and Hindsgaul, respectively, in attaining 2-3 orders of
magnitude improved receptor binding over M6P,
suggests that peptide- or carbohydrate-based linkers
may be advantageous. Both such tethers present Hbond donor/acceptor functionality across the M6P-M6P
span. They also confer more rigidity than a simply sp3-

In closing, we note that the combination of crossmetathesis to build the bivalent sugar scaffold, and bistriflate displacement to introduce the phosphatesurrogate late in the synthesis, is a powerful approach.
This strategy is likely amenable to the introduction of
other phosphate-mimicking functionality in the
endgame, and more generally, is likely extendible to the
study of other multivalent ligand-protein interactions.
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The synthesis of bivalent, M6P-based phosphonates and their evaluation for M6P-IGF2R binding is reported.

